- Home
- PCRX vs SANA Comparison
PCRX vs SANA Comparison
Compare PCRX & SANA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCRX
- SANA
- Stock Information
- Founded
- PCRX 2006
- SANA 2018
- Country
- PCRX United States
- SANA United States
- Employees
- PCRX N/A
- SANA N/A
- Industry
- PCRX Biotechnology: Pharmaceutical Preparations
- SANA Medicinal Chemicals and Botanical Products
- Sector
- PCRX Health Care
- SANA Health Care
- Exchange
- PCRX Nasdaq
- SANA Nasdaq
- Market Cap
- PCRX 1.2B
- SANA 983.4M
- IPO Year
- PCRX 2011
- SANA 2021
- Fundamental
- Price
- PCRX $22.07
- SANA $3.91
- Analyst Decision
- PCRX Buy
- SANA Strong Buy
- Analyst Count
- PCRX 8
- SANA 6
- Target Price
- PCRX $28.38
- SANA $10.00
- AVG Volume (30 Days)
- PCRX 590.9K
- SANA 5.6M
- Earning Date
- PCRX 08-05-2025
- SANA 08-11-2025
- Dividend Yield
- PCRX N/A
- SANA N/A
- EPS Growth
- PCRX N/A
- SANA N/A
- EPS
- PCRX N/A
- SANA N/A
- Revenue
- PCRX $702,772,000.00
- SANA N/A
- Revenue This Year
- PCRX $7.90
- SANA N/A
- Revenue Next Year
- PCRX $11.02
- SANA N/A
- P/E Ratio
- PCRX N/A
- SANA N/A
- Revenue Growth
- PCRX 3.08
- SANA N/A
- 52 Week Low
- PCRX $11.16
- SANA $1.26
- 52 Week High
- PCRX $27.64
- SANA $7.30
- Technical
- Relative Strength Index (RSI)
- PCRX 44.39
- SANA 47.52
- Support Level
- PCRX $20.85
- SANA $4.72
- Resistance Level
- PCRX $22.32
- SANA $5.33
- Average True Range (ATR)
- PCRX 0.84
- SANA 0.35
- MACD
- PCRX 0.01
- SANA -0.14
- Stochastic Oscillator
- PCRX 44.69
- SANA 3.40
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
About SANA Sana Biotechnology Inc.
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs for across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates is comprised of SC291, SC262, SC255, UP421 and others.